Boule Diagnostics AB (BOUL) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Boule Diagnostics Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.938 -- 00:00:07.345 Good morning, everybody, and welcome to the first quarter's earnings call for Bull Diagnostics. 00:00:07.345 -- 00:00:13.193 I'm Holger Lambert, CFO for Bull Diagnostics, and with me, I have our CEO, Torben Nielsen. 00:00:13.193 -- 00:00:18.440 After our presentation, we will open up for questions, but please also feel free to 00:00:18.440 -- 00:00:24.748 type questions in the chat field. With that, I'm handing over to our CEO, Torben Nielsen. 00:00:24.748 -- 00:00:30.335 Yeah, thanks, Holger, and good morning to everyone, and thank you for joining this Q1 00:00:30.335 -- 00:00:32.896 earnings call for 2025. 00:00:33.697 -- 00:00:37.985 We'll begin by taking a look at the highlights of the quarter. 00:00:37.985 -- 00:00:41.627 And overall, it was a bit of a mixed bag. 00:00:41.651 -- 00:00:46.600 Despite a satisfactory order intake in the quarter, we were unable to complete many of 00:00:46.600 -- 00:00:52.009 our orders in time for Q1 close, which led to declining sales of both instruments 00:00:52.009 -- 00:00:54.150 and consumables. 00:00:54.858 -- 00:01:00.243 Due to the geopolitical instability and uncertainty about the US tariff policy, 00:01:00.243 -- 00:01:05.468 many of our core markets in the Middle East and Africa restricted global access to US 00:01:05.468 -- 00:01:10.733 dollars, which led to delayed payments and ultimately delayed shipments 00:01:10.733 -- 00:01:13.574 of instruments and reagents. 00:01:14.637 -- 00:01:19.702 On top of that, we delivered an unusually big order of 600 instruments to India 00:01:19.702 -- 00:01:24.994 in Q1 of last year, which combined then led to an unfavorable 00:01:24.994 -- 00:01:27.577 year-on-year comparison 00:01:27.577 -- 00:01:33.463 of minus 25% total organic growth per quarte...